X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2024-04-04 | HLVX | Frazier Life Sciences X, L.P. | 10% | P - Purchase | $14.50 | +8,850 | 8,544,187 | 0% | +$128,325 | ||||||
| M | 2024-04-03 | HLVX | Kohli Aditya | Dir | S - Sale | $14.69 | -18,000 | 789,776 | -2% | -$264,467 | |||||
2024-03-28 | HLVX | McLoughlin Sean | COO | P - Purchase | $16.98 | +1,250 | 1,250 | New | +$21,225 | ||||||
| EM | 2024-03-18 | HLVX | Kohli Aditya | Dir | S - Sale | $20.81 | -18,000 | 807,776 | -2% | -$374,649 | |||||
| M | 2024-03-06 | HLVX | Kohli Aditya | Dir | S - Sale | $18.66 | -18,000 | 825,776 | -2% | -$335,872 | |||||
| M | 2024-02-20 | HLVX | Kohli Aditya | Dir | S - Sale | $14.95 | -18,000 | 843,776 | -2% | -$269,078 | |||||
2024-02-12 | HLVX | Kohli Aditya | Dir | S - Sale | $15.32 | -6,000 | 861,776 | -1% | -$91,921 | ||||||
| D | 2024-02-08 | HLVX | Kohli Aditya | Dir | S - Sale+OE | $14.93 | -8,866 | 867,776 | -1% | -$132,383 | |||||
| D | 2024-02-08 | HLVX | Maltbie Shane | CFO | S - Sale+OE | $14.93 | -3,576 | 88,178 | -4% | -$53,395 | |||||
| D | 2024-02-08 | HLVX | Hershberg Robert | See Remarks | S - Sale+OE | $14.93 | -11,597 | 1,128,033 | -1% | -$173,161 | |||||
| D | 2024-02-08 | HLVX | Borkowski Astrid | Chief Medical Officer | S - Sale+OE | $14.93 | -3,933 | 214,892 | -2% | -$58,726 | |||||
2023-12-15 | HLVX | Borkowski Astrid | Chief Medical Officer | S - Sale | $15.50 | -10,000 | 165,193 | -6% | -$155,000 | ||||||
| M | 2023-12-01 | HLVX | Borkowski Astrid | Chief Medical Officer | S - Sale | $14.35 | -20,000 | 175,193 | -10% | -$287,000 | |||||
2023-11-17 | HLVX | Borkowski Astrid | Chief Medical Officer | S - Sale | $14.00 | -10,000 | 195,193 | -5% | -$140,000 | ||||||
2023-11-08 | HLVX | Borkowski Astrid | Chief Medical Officer | S - Sale | $13.00 | -5,000 | 205,193 | -2% | -$65,000 | ||||||
| D | 2022-05-03 | HLVX | Frazier Life Sciences X, L.P. | 10% | P - Purchase | $17.00 | +1,764,706 | 8,535,337 | +26% | +$30,000,002 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |